

**DESCRIPTION**


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human CEACAM-20 in direct ELISAs.
<b>Source</b>	Monoclonal Mouse IgG <sub>1</sub> Clone # 1032339
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Human embryonic kidney cell HEK293-derived human CEACAM-20 Gln31-Gly450 Accession # Q6UY09-1
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

**APPLICATIONS**

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Flow Cytometry</b>	0.25 µg/10 <sup>6</sup> cells	HEK293 Human Cell Line Transfected with Human CEACAM-20 and eGFP

**DATA**



**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

Carcinoembryonic antigen-related cell adhesion molecule-20 (CEACAM-20) is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily. Mature human CEACAM-20 consists of a 420 amino acid (aa) extracellular domain (ECD), a 21 aa helical transmembrane segment, and a 114 aa cytoplasmic domain. The extracellular domain possesses four IgC2-like domains which are stabilized by disulfide bonds, as well as several predicted glycosylation sites (1-5). The extracellular domain of CEACAM-20 is also unique among the CEACAMs because it contains a truncated IgV-like N domain (2). Within the ECD, human CEACAM-20 shares 64% and 62% aa identity with the mouse and rat CEACAM-20, respectively. The cytoplasmic domain is unusually long compared to other CEACAMs and is predicted to contain four tyrosine phosphorylation sites, two of which correspond to the immune-receptor tyrosine-based activation motif (ITAM) (2, 3). Human CEACAM proteins have been linked to numerous intercellular-adhesion and intracellular signaling processes including cell adhesion, growth, and recognition, differentiation, angiogenesis, and apoptosis (7, 8). Human CEACAM-20 expression is limited to the reproductive system and the intestinal tract, with the highest levels of expression found in the small intestine and prostate (2, 3). An *in vitro* model of human prostate morphogenesis showed that CEACAM-20 is co-expressed with CEACAM-1 and plays a critical role in the formation of prostate organoids, making it a marker for prostate cancer (2). Although the exact mechanism is not fully understood, CEACAM-20 may promote the proliferation of intestinal epithelial cells (IECs) (9). There is evidence suggesting CEACAM-20 can induce the production of chemokines like interleukin (IL)-8 and stimulate inflammatory responses in colitis and Crohn's disease (6). CEACAM-20 is also thought to act as a physiological substrate for SAP-1 in the intestinal epithelium (10).

## References:

1. Tchoupa, A. *et al.* (2014) *J Cell Commun Signal* **12**:27.
2. Zhang, H. *et al.* (2013) *PLoS ONE* **8**:e53359.
3. Zebhauser, R. *et al.* (2005) *Genomics* **86**:566.
4. Beauchemin, N. Arabzadeh, A. (2013) *Cancer Metastasis Rev* **32**(3):643.
5. Kuespert, K. *et al.* (2006) *Curr Opin Cell Biol* **18**:565.
6. Murata, Y. *et al.* (2015) *PNAS* E4264.
7. Obrink, B. (1997) *Curr Opin Cell Biol* **9**:616.
8. Horst, AK. Wagener, C. (2004) *Handb Exp Pharmacol* 283.
9. Kitamura, Y. *et al.* (2015) *Genes to Cells* **20**:578.
10. Kotani, T. *et al.* (2016) *Expert Review of Gastroenterology & Hepatology*. **10**:1313.